Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
CRISPR Therapeutics AG | Chief Financial Officer | Common Shares | 1.89K | $118K | $62.50 | Aug 6, 2021 | Direct |
CRISPR Therapeutics AG | Chief Financial Officer | Stock Option (Right to Buy) | 131K | Mar 11, 2021 | Direct | ||
Milestone Pharmaceuticals Inc. | Director | Stock Option (right to buy) | 40K | Aug 28, 2024 | Direct | ||
Acrivon Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 20.3K | Jun 20, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
MIST | Milestone Pharmaceuticals Inc. | Aug 28, 2024 | 1 | $0 | 4 | Aug 29, 2024 | Director |
ACRV | Acrivon Therapeutics, Inc. | Jun 20, 2024 | 1 | $0 | 4 | Jun 24, 2024 | Director |
MIST | Milestone Pharmaceuticals Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
ACRV | Acrivon Therapeutics, Inc. | Nov 14, 2022 | 1 | $0 | 4 | Nov 16, 2022 | Director |
ACRV | Acrivon Therapeutics, Inc. | Nov 9, 2022 | 0 | $0 | 3 | Nov 9, 2022 | Director |
MIST | Milestone Pharmaceuticals Inc. | Oct 19, 2022 | 1 | $79.8K | 4 | Oct 21, 2022 | Director |
MIST | Milestone Pharmaceuticals Inc. | Jul 5, 2022 | 1 | $0 | 4 | Aug 11, 2022 | Director |
CRSP | CRISPR Therapeutics AG | Aug 6, 2021 | 4 | -$3.02M | 4 | Aug 10, 2021 | Chief Financial Officer |
MIST | Milestone Pharmaceuticals Inc. | Jun 14, 2021 | 1 | $0 | 4 | Jul 29, 2021 | Director |